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Aims Valvular heart disease can be identified by calcification on coronary computed tomography angiography (CCTA)
and has been associated with adverse clinical outcomes. We assessed aortic and mitral valve calcification in patients





In 1769 patients (58 ± 9 years, 56% male) undergoing CCTA for stable chest pain, aortic and mitral valve
calcification were quantified using Agatston score. Aortic valve calcification was present in 241 (14%) and mitral
calcification in 64 (4%). Independent predictors of aortic valve calcification were age, male sex, hypertension,
diabetes mellitus, and cerebrovascular disease, whereas the only predictor of mitral valve calcification was age.
Patients with aortic and mitral valve calcification had higher coronary artery calcium scores and more obstructive
coronary artery disease. The composite endpoint of cardiovascular mortality, non-fatal myocardial infarction, or
non-fatal stroke was higher in those with aortic [hazard ratio (HR) 2.87; 95% confidence interval (CI) 1.60–5.17;
P < 0.001] or mitral (HR 3.50; 95% CI 1.47–8.07; P = 0.004) valve calcification, but this was not independent of
coronary artery calcification or obstructive coronary artery disease.
...................................................................................................................................................................................................
Conclusion Aortic and mitral valve calcification occurs in one in six patients with stable chest pain undergoing CCTA and is
associated with concomitant coronary atherosclerosis. Whilst valvular calcification is associated with a higher risk
of cardiovascular events, this was not independent of the burden of coronary artery disease.
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Introduction
Valvular heart disease is an important cause of morbidity and mortal-
ity worldwide and shares similar risk factors with coronary artery dis-
ease.1 Incidental calcification of the aortic or mitral valve on
computed tomography (CT) may identify patients with previously
undiagnosed valvular heart disease. Coronary CT angiography
(CCTA) is now a widely used non-invasive imaging modality,
frequently the first-line investigation for patients with suspected
coronary artery disease.2,3 Therefore, the identification of incidental
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..valvular calcification on CCTA represents a potentially important
opportunity for screening and patient risk stratification.4–7
Aortic valve calcification is an established marker of aortic stenosis,
with the aortic valve calcium score on CT associated with hemo-
dynamic severity of aortic stenosis on echocardiography.8–10 Robust
sex-specific aortic valve CT calcium score thresholds for severe aor-
tic stenosis have been proposed, validated,11,12 and recommended in
recent international guidelines for the assessment of aortic stenosis
severity when echocardiographic assessments are discordant.13
Mitral valve annular calcification is also a frequent finding on CCTA
and may be associated with mitral valve dysfunction.14,15 Previous
studies have suggested that patients with aortic stenosis and mitral
valve calcification have an increased frequency of cardiovascular
mortality beyond that related to the valve, including an increased risk
of myocardial infarction (MI) and stroke, although the mechanisms
underlying these associations remain unclear.7,16,17
In this study, we identified the prevalence and severity of incidental
aortic and mitral valve calcification in patients undergoing CT as part
of the Scottish COmputed Tomography of the HEART (SCOT-
HEART) trial, and assessed their association with cardiovascular risk
factors, coronary artery disease, and cardiovascular outcomes.
Methods
Study design
In the SCOT-HEART multicentre randomized controlled trial, 4146
patients with suspected angina due to coronary artery disease were
randomized to undergo either standard care or standard care and
CT.18The primary results of the SCOT-HEART trial have been pub-
lished previously.19–21 Of the 1778 patients who subsequently under-
went CT, 1769 images were available for analysis and included in this
sub-study. Imaging included non-contrast CT for coronary artery cal-
cium score and CCTA. The study was approved by the local ethics
committee and participants provided written informed consent. The




Demographic information and information on cardiovascular risk factors
were collected prospectively within the SCOT-HEART trial and obtained
from the SCOT-HEART database.
Computed tomography
CT imaging was performed using a 64 (Brilliance 64, Philips Medical
Systems, Netherlands and Biograph mCT, Siemens, Germany) or 320
multidetector (Aquilion ONE, Toshiba Medical Systems, Japan) scanner.
Non-contrast electrocardiogram-gated CT for coronary calcium
scoring and contrast-enhanced CCTA were performed as described
previously.18
Assessment of valvular calcification
All CCTA images were visually assessed for the presence of aortic or mi-
tral valve/annulus calcification (Figure 1). Quantitative assessment of the
aortic valve and mitral calcification was performed on non-contrast CT
imaging using the Agatston scoring method as previously
described.12,15,22Non-contrast images with 3-mm slices and 3-mm incre-
ment were assessed using semi-automatic software (VScore, Vital Images,
USA). A threshold of 130 Hounsfield units was used for the identification
of calcification. For cases where the location of the valve was uncertain
on non-contrast images, contrast-enhanced CCTA was used to visually
confirm the anatomy.
Clinical outcomes
Outcome information was obtained from national electronic health link-
age data provided by the electronic Data Research and Innovation
Service (eDRIS) of the National Health Service (NHS) Scotland.
Outcomes were confirmed by review of the patient health records
Figure 1 Calcification of the aortic (A) and mitral (B) annulus (yellow arrow in patients with co-existing coronary artery disease (white arrow).















































where required. Surgical coding information was used to identify patients
who underwent aortic or mitral valve surgery using the OPCS (Office of
Population Censuses and Surveys) 4 Classification of Surgical Operations
and Procedures.
Statistical analysis
The primary composite endpoint of this sub-study was cardiovascular
mortality, non-fatal MI, or non-fatal stroke. Quantitative data are pre-
sented as mean and standard deviation or, if the data were not nor-
mally distributed, median and interquartile intervals. Statistical
significance was assessed using Pearson’s v2 test, Fisher’s exact test,
Students t-test, or Mann–Whitney U test, as appropriate.
Correlations were assessed using Spearman’s rank order correlation
(0–0.19 very weak, 0.2–0.39 weak, 0.40–0.59 moderate, 0.6–0.79
strong, and 0.8–1 very strong). Hazard ratios (HRs) and 95% confi-
dence intervals (CIs) are presented. Ordinal regression analysis was
performed to assess the effect of cardiovascular risk factors on aortic
and mitral valve calcification. Multivariable analysis was performed
including valvular calcification, coronary artery calcification, and the
presence of obstructive coronary artery disease. Outcome data were
analysed using Cox proportional hazards regression and presented
graphically using cumulative incidence plots of the time to the first
event. Statistical analysis was performed using R version 3.5.0 (R
Foundation for Statistical Computing, Vienna, Austria). A statistically
significant difference was defined as a two-sided P-value <0.05.
Results
Study population
Of the 4146 patients recruited into the study, 2073 were randomized
to CT and 1769 CT scans were available and of suitable quality for
analysis. Valvular calcification (Table 1) was identified in 273 (15%)
patients, with aortic valve calcification occurring in 241 (14%) patients,
mitral calcification in 64 (4%) patients, and combined aortic and mitral
calcification in 32 (2%) patients. After 4.82 ± 1.13 years of follow-up,
53 patients had met the composite endpoint: cardiovascular mortality
(n = 4), non-fatal MI (n = 38), or non-fatal stroke (n = 11).
Aortic valve calcification
Independent predictors of the presence of aortic valve calcification
(Figure 2) were age [odds ratio (OR) 1.11; 95% CI 1.08–1.15;
P < 0.001], male sex (OR 2.62; 95% CI 1.87–3.70; P < 0.001), hyper-
tension (OR 1.39, 95% CI 1.02–1.88; P = 0.037), diabetes mellitus
(OR 1.81; 95% CI 1.09–2.97; P = 0.020), and a prior history of cere-
brovascular disease (OR 2.30; 95% CI 1.32–3.96; P = 0.003).
Patients with aortic valve calcification had a higher coronary artery
calcium score [390 (interquartile range, IQR 61–1105) Agatston units
(AU)] compared to those without aortic valve calcification [8 (IQR
0–145) AU, P < 0.001, Figure 3]. Patients with aortic valve calcification
..................................................... ....................................................
....................................................................................................................................................................................................................
Table 1 Characteristics of study participants
All participants Aortic valve calcification Mitral valve calcification
P-value P-value
N 1769 241 (14%) 64 (4%)
Male 997 (56%) 178 (74%) <0.001 41 (64%) 0.206
Age (years) 58 ± 9 64 ± 7 <0.001 65 ± 7 <0.001
Body mass index (kg/m2) 30 ± 6 30 ± 5 0.896 30 ± 5 0.386
Atrial fibrillation 34 (2%) 7 (3%) 0.213 2 (3%) 0.350
Smoking status
Current smoker 330 (19%) 37 (15%) 0.007 5 (8%) 0.007
Ex-smoker 593 (34%) 102 (42%) 32 (50%)
Non-smoker 845 (48%) 102 (42%) 27 (43%)
Hypertension 608 (35%) 122 (51%) <0.001 36 (57%) <0.001
Diabetes Mellitus 196 (11%) 45 (19%) <0.001 14 (22%) 0.005
Family history CHD 765 (45%) 91 (38%) 0.048 20 (32%) 0.053
Previous CHD 178 (10%) 39 (16%) <0.001 11 (17%) 0.054
Previous PAD 31 (2%) 7 (3%) 0.178 1 (2%) 1
Previous CVD 79 (4%) 27 (11%) <0.001 6 (10%) 0.059
Total cholesterol
concentration (mg/dL)
192 ± 73 179 ± 74 0.003 182 ± 85 0.324
Anginal symptoms
Typical angina 654 (37%) 124 (51%) <0.001 33 (52%) 0.046
Atypical angina 432 (24%) 66 (27%) 11 (17%)
Non-anginal 683 (39%) 51 (21%) 20 (31%)
Risk score 17.9 ± 11.0 24.6 ± 11.1 <0.001 25.5 ± 11.5 <0.001
Data are presented as N (%), mean ± standard deviation, or median (interquartile range).
P-values represent comparison to total cohort.
CHD, coronary heart disease; CTCA, computed tomography coronary angiography; CVD, cerebrovascular disease; PAD, peripheral arterial disease.
Bold values indicate statistical significance.








































..were also more likely to have non-obstructive (41%) or obstructive
(51%) coronary artery disease than patients without aortic valve calcifi-
cation (P < 0.001). However, 9% (n = 21/241) of patients with aortic
valve calcification had no coronary artery calcification, and 80%
(n = 907/1127) of patients with coronary artery calcification had no aor-
tic valve calcification. A correlation was observed between the aortic
valve calcium score and coronary artery calcium score, but this was
only weak (r = 0.23, P < 0.001, Figure 3).
A higher proportion of patients with aortic valve calcification met
the composite endpoint compared to patients without aortic valve
calcification [6.6% (n = 16/241) vs. 2.4% (n = 37/1528), P = 0.002; HR
2.87; 95% CI 1.60–5.17; P < 0.001 (Figure 4)]. However, on multivari-
able analysis, only coronary artery calcium score was an independent
predictor of the composite endpoint (Table 2).
Mitral valve calcification
The only independent predictor of the presence of mitral valve calci-
fication (Figure 2) was age (OR 1.09; 95% CI 1.03–1.15; P = 0.002).
Patients with mitral calcification had a higher coronary artery calcium
score [413 (IQR 36–1056) AU] compared to those without mitral
calcification [18 (IQR 0–202) AU, P < 0.001, Figure 4]. Patients with
mitral calcification were also more likely to have both non-
obstructive (45%) and obstructive (44%) coronary artery disease
compared to patients without (P < 0.001). However, 14% (n = 9/64)
of patients with mitral calcification had no coronary artery calcifica-
tion, and 95% (n = 1072/1127) of patients with coronary artery calcifi-
cation had no mitral calcification. There was no correlation between
mitral valve calcium score and coronary artery calcium score
(r = 0.03, P = 0.68, Figure 4).
Patients with mitral valve calcification were more likely to meet
the composite endpoint compared to patients without mitral valve
calcification [9.4% (n = 6/64) vs. 2.8% (n = 47/1705), P = 0.01]: HR
3.50; 95% CI 1.47–8.07; P = 0.004 (Figure 4). However, on multivari-
able analysis only coronary artery calcium score was an independent
predictor of the composite endpoint (Table 3).
Discussion
In this large multicentre randomized controlled trial of patients
undergoing CT for stable chest pain, we have shown that valvular
Figure 2 Multivariable analysis of cardiovascular risk factors and the presence of aortic valve or mitral calcification. Age (years); male gender com-
pared to female gender; smoking status compared to non-smokers; total cholesterol concentration per unit increment; symptoms compared to those
with non-anginal chest pain; Risk_score, ASSIGN cardiovascular risk score; AF, atrial fibrillation; BMI, body mass index; CHD, previous history of cor-
onary heart disease; CVD, previous history of cerebrovascular disease; FH, family history of coronary heart disease; HBP, hypertension; PVD, previous
history of peripheral vascular disease; *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 3 Coronary artery calcification was higher in patients with both (A) aortic valve calcification and (B) mitral valve calcification than patients
without. Correlation between coronary artery Agatston calcium score and (C) aortic valve calcium score and (D) mitral valve calcium score. *log
transformed.
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Figure 4 Cumulative incidence plot showing the association of the presence of (A) aortic valve calcification and (B) mitral calcification on the com-
posite endpoint of cardiovascular death (CVD), non-fatal myocardial infarction (NFMI), or non-fatal stroke (NFS). The adverse outcomes associated
with valve calcification were no longer evident once the burden of coronary atherosclerosis was considered in the multivariable model.














































..calcification is a common incidental finding, occurring in one in six
patients. Aortic and mitral valve calcifications are associated with
traditional cardiovascular risk factors and underlying coronary artery
disease. Whilst patients with aortic or mitral calcification were three
times more likely to suffer an adverse cardiovascular event, this effect
was not independent of the burden of coronary artery disease. This
indicates that the adverse prognosis associated with valve calcification
in these patients is mediated by its association with coronary artery
disease, rather than representing a direct causal effect.
In our study, valvular calcification was associated with a three-fold
increased risk of cardiovascular death, MI, or stroke, but this was not
independent of coronary artery calcium score, a marker of athero-
sclerotic plaque burden. Similar results were reported in a study of
lung cancer screening patients, in whom aortic valve calcification did
not provide incremental prognostic information over coronary calci-
fication.23 This is in contrast to previous studies which reported an
association between aortic stenosis or mitral valve calcification and
adverse cardiovascular outcomes. In the Cardiovascular Health Study
(CHS) study of patients over 65 years old, the presence of aortic
stenosis on echocardiography was associated with a 50% increase in
the risk of cardiovascular death and MI.24 In the Multi-Ethnic Study
of Atherosclerosis (MESA) primary prevention study, the presence
of aortic valve calcification was associated with a 72% increased
risk of MI and 50% increase in the risk of cardiovascular events.25
However, similar to our study, this effect was no longer statistically
significant after adjustment for cardiovascular risk factors, inflamma-
tory biomarkers and coronary artery calcium score.25 We therefore
provide further evidence to support the theory that cardiovascular
events in patients with valvular calcification are driven by the associ-
ation with coronary artery disease, rather than the presence of valvu-
lar heart disease itself.
In this study, we have confirmed the close association between
valve calcification and both cardiovascular risk factors and coronary
atherosclerosis. Similar to previous studies,15,26–28 we found that age,
male sex, hypertension, diabetes, and prior history of cerebrovascu-
lar disease were independent predictors of aortic valve calcification,
whilst age was the only independent predictors of mitral calcification.
This suggests that there are overlapping but distinct mechanisms
underlying these pathologies.
The vast majority of patients with aortic and mitral valve calcifica-
tion had evidence of co-existent coronary calcification on CT calcium
scoring, reflecting the pathological overlap between atherosclerosis
and the early stages of both aortic and mitral valve calcification, as
well as shared risk factors for these conditions.25,29–31 However, the
correlation between coronary artery calcification and aortic valve
calcium scores was poor, and there was no correlation with mitral
calcium scores. Although most patients with valvular heart disease
had obstructive or non-obstructive coronary artery disease, few
....................................................................................................................................................................................................................
Table 2 Univariable and multivariable analysis for aortic valve calcification and the composite endpoint of cardiovas-
cular mortality, non-fatal myocardial infarction, or non-fatal stroke
Univariable Multivariable
Aortic valve calcification 2.87 (95% CI 1.60–5.17)
P < 0.001
1.75 (95% CI 0.93–3.29)
P = 0.081
Coronary artery calcificationa 1.18 (95% CI 1.10–1.27)
P < 0.001
1.12 (95% CI 1.02–1.22)
P = 0.022
Obstructive coronary artery disease 2.94 (95% CI 1.72–5.04)
P < 0.001





Table 3 Univariable and multivariable analysis for mitral valve calcification and the composite endpoint of cardiovas-
cular mortality, non-fatal myocardial infarction, or non-fatal stroke
Univariable Multivariable
Mitral valve calcification 3.45 (95% CI 1.50–8.07)
P = 0.004
2.21 (95% CI 0.92–5.28)
P = 0.075
Coronary artery calcificationa 1.18 (95% CI 1.10–1.27)
P < 0.001
1.13 (95% CI 1.03–1.24)
P = 0.012
Obstructive coronary artery disease 2.94 (95% CI 1.72–5.04)
P < 0.001





































































































patients with coronary artery disease had valvular heart disease.
Thus, the presence of valvular heart disease could be a trigger to as-
sess the coronary arteries, but the presence of coronary artery dis-
ease is not an indication for valvular assessment with
echocardiography.
Our study has several limitations. This includes the small number
of clinical events and that patients were managed according to
routine clinical practice rather than having management prescribed
on the basis of the imaging findings. The prevalence of valvular calcifi-
cation and cardiovascular risk factors varies depending on the cohort
studied. The age range of the SCOT-HEART population meant
that mild calcification was the most common pathology and that the
5-year duration of follow-up might not have been sufficient for this
early stage of disease to result in clinical events. In addition, the
SCOT-HEART participants were recruited from cardiology out-
patient clinics with suspected angina due to coronary artery disease.
Although two-thirds of the patients were ultimately diagnosed as not
having angina due to coronary artery disease, these results may not
be representative of asymptomatic patients or the general popula-
tion. Finally, we do not have data on the progression of valve calcifica-
tion in this cohort which in other studies appears unrelated to
cardiovascular risk factors but is most closely associated with the se-
verity of baseline valve disease and calcification.
Conclusion
Valvular calcification is a frequent incidental finding on CCTA and is
associated with cardiovascular risk factors and the presence of
coronary artery disease. Whilst patients with aortic or mitral valve
calcification demonstrate a three-fold increased risk of future adverse
cardiovascular events, this appears to be mediated by co-existent
coronary artery disease.
Supplementary data
Supplementary data are available at European Heart Journal - Cardiovascular
Imaging online.
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